Propanc Biopharma (PPCB) Return on Invested Capital (2011 - 2024)
Propanc Biopharma (PPCB) posted quarterly Return on Invested Capital of 0.01% for Q2 2024, little changed year-over-year from 0.01% in Q3 2023, and up 10.79% quarter-over-quarter from 0.01% in Q1 2024.
Propanc Biopharma (PPCB) Return on Invested Capital (2011 - 2024) Analysis & Trends
Propanc Biopharma (PPCB) has reported Return on Invested Capital for 14 consecutive years, with 0.01% the latest figure, recorded in Q2 2024.
- In Q2 2024, Return on Invested Capital changed 0.0% year-over-year to 0.01%; the TTM figure through Jun 2024 stood at 0.01% (changed 0.0% YoY), while the FY2024 annual figure was 0.04%, down 1.0% from the prior year.
- Return on Invested Capital grew to 0.01% in Q2 2024 per PPCB's latest filing, from 0.01% in the prior quarter.
- Across five years, Return on Invested Capital topped out at 0.0% in Q1 2021 and bottomed at 0.01% in Q1 2020.
- Historically, Return on Invested Capital has averaged 0.01% across 5 years, with a median of 0.01% in 2024.
- Annual changes were most pronounced in 2020 — Return on Invested Capital decreased 1 bps — and 2021, when it rose 1 bps.
- Propanc Biopharma's Return on Invested Capital stood at 0.0% in 2020, then slumped by 117 bps to 0.01% in 2021, then soared by 32 bps to 0.01% in 2022, then plunged by 72 bps to 0.01% in 2023, then jumped by 35 bps to 0.01% in 2024.
- Business Quant data shows PPCB's Return on Invested Capital at 0.01% in Q2 2024, 0.01% in Q1 2024, and 0.01% in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.04% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -0.17% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.00% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.35% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -0.01% |
| Mar 31, 2024 | -0.01% |
| Dec 31, 2023 | -0.01% |
| Jun 30, 2023 | -0.01% |
| Mar 31, 2023 | -0.01% |
| Dec 31, 2022 | -0.01% |
| Jun 30, 2022 | -0.01% |
| Mar 31, 2022 | -0.01% |
| Dec 31, 2021 | -0.01% |
| Jun 30, 2021 | -0.01% |
| Mar 31, 2021 | 0.00% |
| Dec 31, 2020 | 0.00% |
| Jun 30, 2020 | -0.01% |
| Mar 31, 2020 | -0.01% |
| Dec 31, 2019 | -0.01% |
| Sep 30, 2019 | 0.00% |
| Jun 30, 2019 | 0.00% |
| Mar 31, 2019 | 0.00% |
| Dec 31, 2018 | 0.00% |
| Jun 30, 2018 | -0.01% |